Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer

OKUTURLAR, Yıldız; Gunaldi, Meral; Kocoglu, Hakan; Hursitoglu, Mehmet; GEDİKBAŞI, Asuman; Acarer, Didem; Harmankaya, Ozlem; Kumbasar, Abdulbaki

doi:10.4103/0973-1482.235355

Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer

Copy For Citation

OKUTURLAR Y., Gunaldi M., Kocoglu H., Hursitoglu M., GEDİKBAŞI A., Acarer D., ...More

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.14, 2018 (SCI-Expanded)

Publication Type: Article / Article
Volume: 14
Publication Date: 2018
Doi Number: 10.4103/0973-1482.235355
Journal Name: JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Keywords: Arylesterase, breast cancer, cancer risk, cut-off value, neoadjuvant, paraoxonase, screening, BODY-MASS INDEX, COLORECTAL-CANCER, OXIDATIVE STRESS, CARCINOGENESIS, INFLAMMATION, POLYMORPHISM, RADICALS, PON1, RISK
Istanbul University Affiliated: Yes

Abstract

Aim: The aims of this study are to evaluate the serum levels of paraoxonase (PON) and arylesterase (ARE) in breast cancer (BC) patients; to determine their relationship with chemotherapy requirements in BC; and to find a cut-off value to assess subjects with a higher risk of BC.